Lenalidomid HEXAL 15 mg Hartkapseln

A Phase 2 Study to Evaluate Safety and Efficacy of Teclistamab-,Talquetamab- and JNJ-79635322-based Combination Regimens in Participants with Newly Diagnosed Transplant Eligible Multiple Myeloma

A randomized phase III non-inferiority trial assessing lenalidomide, bortezomib and dexamethasone induction therapy with either intravenous or subcutaneous isatuximab in transplant-eligible patients with newly diagnosed multiple myeloma (GMMG HD8/ DSMM XIX)